You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameAprotinin
Accession NumberDB06692
TypeBiotech
GroupsApproved, Withdrawn
DescriptionAprotinin, also known as bovine pancreatic trypsin inhibitor, BPTI (Trasylol, Bayer) is a protein, that is used as medication administered by injection to reduce bleeding during complex surgery, such as heart and liver surgery. Its main effect is the slowing down of fibrinolysis, the process that leads to the breakdown of blood clots. The aim in its use is to decrease the need for blood transfusions during surgery, as well as end-organ damage due to hypotension (low blood pressure) as a result of marked blood loss. The drug was temporarily withdrawn worldwide in 2007 after studies suggested that its use increased the risk of complications or death; after this was confirmed by follow-up studies, Trasylol was entirely and permanently withdrawn in May 2008, except - at least for the time being - for very restricted research use. [Wikipedia]
Protein structureDb06692
Related Articles
Protein chemical formulaC284H432N84O79S7
Protein average weight6511.439 Da
Sequences
>Aprotinin (bovine pancreatic trypsin inhibitor)
RPDFCLEPPYTGPCKARIIRYFYNAKAGLCQTFVYGGCRAKRNNFKSAEDCMRTCGGA
Download FASTA Format
Synonyms
Aprotinin (bovine)
Aprotinin Biosynthetic
Aprotinin Bovine
Aprotinin Concentrated Solution
Bovine Aprotinin
Bovine Pancreatic Trypsin Inhibitor
BPTI
Fibrinolysis Inhibitor
Trypsin Inhibitor, Pancreatic Basic
External Identifiers
  • 232-994-9
  • Bayer A 128
  • Bayer-A-128
  • Riker-52G
  • RP-9921
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
TrasylolSolution10000 unitIntravenousNordic Group B.V.1997-12-15Not applicableCanada
Trasylol Inj 10000 Kiu/mlLiquid100000 unitIntravenousMiles Canada Inc. Pharmaceutical Division1981-12-311998-09-25Canada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII04XPW8C0FL
CAS number9087-70-1
Pharmacology
IndicationFor prophylactic use to reduce perioperative blood loss and the need for blood transfusion in patients undergoing cardiopulmonary bypass in the course of coronary artery bypass graft surgery who are at an increased risk for blood loss and blood transfusion.
Structured Indications Not Available
PharmacodynamicsAprotinin is a broad spectrum protease inhibitor which modulates the systemic inflammatory response (SIR) associated with cardiopulmonary bypass (CPB) surgery. SIR results in the interrelated activation of the hemostatic, fibrinolytic, cellular and humoral inflammatory systems. Aprotinin, through its inhibition of multiple mediators [e.g., kallikrein, plasmin] results in the attenuation of inflammatory responses, fibrinolysis, and thrombin generation. Aprotinin inhibits pro-inflammatory cytokine release and maintains glycoprotein homeostasis. In platelets, aprotinin reduces glycoprotein loss (e.g., GpIb, GpIIb/IIIa), while in granulocytes it prevents the expression of pro-inflammatory adhesive glycoproteins (e.g., CD11b). The effects of aprotinin use in CPB involves a reduction in inflammatory response which translates into a decreased need for allogeneic blood transfusions, reduced bleeding, and decreased mediastinal re-exploration for bleeding.
Mechanism of actionAprotinin inhibits several serine proteases, specifically trypsin, chymotrypsin and plasmin at a concentration of about 125,000 IU/ml, and kallikrein at 300,000 IU/ml. Its action on kallikrein leads to the inhibition of the formation of factor XIIa. As a result, both the intrinsic pathway of coagulation and fibrinolysis are inhibited. Its action on plasmin independently slows fibrinolysis.
TargetKindPharmacological actionActionsOrganismUniProt ID
Trypsin-1ProteinunknownNot AvailableHumanP07477 details
Chymotrypsinogen BProteinunknownNot AvailableHumanP17538 details
PlasminogenProteinunknownNot AvailableHumanP00747 details
Kallikrein-1ProteinunknownNot AvailableHumanP06870 details
Related Articles
Absorption100% (IV)
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Aprotinin is slowly degraded by lysosomal enzymes.

Route of eliminationFollowing a single IV dose of radiolabelled aprotinin, approximately 25-40% of the radioactivity is excreted in the urine over 48 hours. After a 30 minute infusion of 1 million KIU, about 2% is excreted as unchanged drug. After a larger dose of 2 million KIU infused over 30 minutes, urinary excretion of unchanged aprotinin accounts for approximately 9% of the dose.
Half lifeFollowing this distribution phase, a plasma half-life of about 150 minutes is observed. At later time points, (i.e., beyond 5 hours after dosing) there is a terminal elimination phase with a half-life of about 10 hours.
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Aprotinin Action PathwayDrug actionSMP00288
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AbacavirThe serum concentration of Abacavir can be decreased when it is combined with Aprotinin.Approved, Investigational
AbciximabThe therapeutic efficacy of Abciximab can be decreased when used in combination with Aprotinin.Approved
AcenocoumarolThe therapeutic efficacy of Acenocoumarol can be decreased when used in combination with Aprotinin.Approved
Acetylsalicylic acidThe therapeutic efficacy of Acetylsalicylic acid can be decreased when used in combination with Aprotinin.Approved, Vet Approved
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Aprotinin.Approved, Investigational
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Aprotinin.Approved, Illicit, Investigational
AlteplaseThe therapeutic efficacy of Alteplase can be decreased when used in combination with Aprotinin.Approved
ALX-0081The therapeutic efficacy of ALX-0081 can be decreased when used in combination with Aprotinin.Investigational
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Aprotinin.Experimental
AmineptineThe serum concentration of Amineptine can be increased when it is combined with Aprotinin.Illicit, Withdrawn
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Aprotinin.Approved
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Aprotinin.Approved
AnagrelideThe therapeutic efficacy of Anagrelide can be decreased when used in combination with Aprotinin.Approved
AncrodThe therapeutic efficacy of Ancrod can be decreased when used in combination with Aprotinin.Investigational
AnistreplaseThe therapeutic efficacy of Anistreplase can be decreased when used in combination with Aprotinin.Approved
ApixabanThe therapeutic efficacy of Apixaban can be decreased when used in combination with Aprotinin.Approved
ArdeparinThe therapeutic efficacy of Ardeparin can be decreased when used in combination with Aprotinin.Approved, Withdrawn
ArgatrobanThe therapeutic efficacy of Argatroban can be decreased when used in combination with Aprotinin.Approved, Investigational
AstaxanthinThe therapeutic efficacy of Astaxanthin can be decreased when used in combination with Aprotinin.Investigational
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Aprotinin.Approved
BatroxobinThe therapeutic efficacy of Batroxobin can be decreased when used in combination with Aprotinin.Experimental
BemiparinThe therapeutic efficacy of Bemiparin can be decreased when used in combination with Aprotinin.Approved
BenazeprilAprotinin may decrease the antihypertensive activities of Benazepril.Approved, Investigational
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Aprotinin.Investigational
BivalirudinThe therapeutic efficacy of Bivalirudin can be decreased when used in combination with Aprotinin.Approved, Investigational
BoceprevirThe serum concentration of Aprotinin can be decreased when it is combined with Boceprevir.Approved
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Aprotinin.Approved, Investigational
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Aprotinin.Approved
CandoxatrilAprotinin may decrease the antihypertensive activities of Candoxatril.Experimental
CangrelorThe therapeutic efficacy of Cangrelor can be decreased when used in combination with Aprotinin.Approved
CaptoprilAprotinin may decrease the antihypertensive activities of Captopril.Approved
CarbamazepineThe metabolism of Aprotinin can be increased when combined with Carbamazepine.Approved, Investigational
ChlorotrianiseneThe serum concentration of Chlorotrianisene can be decreased when it is combined with Aprotinin.Withdrawn
CilazaprilAprotinin may decrease the antihypertensive activities of Cilazapril.Approved
CilostazolThe therapeutic efficacy of Cilostazol can be decreased when used in combination with Aprotinin.Approved
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Aprotinin.Approved, Investigational, Withdrawn
ClarithromycinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Aprotinin.Approved
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with Aprotinin.Approved, Vet Approved
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Aprotinin.Approved, Nutraceutical
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Aprotinin.Approved
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be increased when it is combined with Aprotinin.Approved
CyclophosphamideThe risk or severity of adverse effects can be increased when Aprotinin is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Aprotinin.Approved, Investigational, Vet Approved
Dabigatran etexilateThe therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Aprotinin.Approved
DalteparinThe therapeutic efficacy of Dalteparin can be decreased when used in combination with Aprotinin.Approved
DanaparoidThe therapeutic efficacy of Danaparoid can be decreased when used in combination with Aprotinin.Approved, Withdrawn
DefibrotideThe therapeutic efficacy of Defibrotide can be decreased when used in combination with Aprotinin.Approved, Investigational
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Aprotinin.Approved
DesipramineThe serum concentration of Desipramine can be increased when it is combined with Aprotinin.Approved
DesirudinThe therapeutic efficacy of Desirudin can be decreased when used in combination with Aprotinin.Approved
DesmoteplaseThe therapeutic efficacy of Desmoteplase can be decreased when used in combination with Aprotinin.Investigational
DicoumarolThe therapeutic efficacy of Dicoumarol can be decreased when used in combination with Aprotinin.Approved
DienestrolThe serum concentration of Dienestrol can be decreased when it is combined with Aprotinin.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Aprotinin.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Aprotinin.Approved
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with Aprotinin.Approved
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Aprotinin.Approved
DipyridamoleThe therapeutic efficacy of Dipyridamole can be decreased when used in combination with Aprotinin.Approved
DitazoleThe therapeutic efficacy of Ditazole can be decreased when used in combination with Aprotinin.Approved, Withdrawn
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Aprotinin.Approved
DoxepinThe serum concentration of Doxepin can be increased when it is combined with Aprotinin.Approved
Drotrecogin alfaThe therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Aprotinin.Approved, Investigational, Withdrawn
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Aprotinin.Approved
EnalaprilAprotinin may decrease the antihypertensive activities of Enalapril.Approved, Vet Approved
EnalaprilatAprotinin may decrease the antihypertensive activities of Enalaprilat.Approved
EnfuvirtideThe serum concentration of Enfuvirtide can be increased when it is combined with Aprotinin.Approved, Investigational
EnoxaparinThe therapeutic efficacy of Enoxaparin can be decreased when used in combination with Aprotinin.Approved
eplivanserineThe therapeutic efficacy of eplivanserine can be decreased when used in combination with Aprotinin.Investigational
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Aprotinin.Approved
EptifibatideThe therapeutic efficacy of Eptifibatide can be decreased when used in combination with Aprotinin.Approved, Investigational
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Aprotinin.Approved
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Aprotinin.Approved
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Aprotinin.Approved
EsmirtazapineThe serum concentration of Esmirtazapine can be increased when it is combined with Aprotinin.Investigational
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Aprotinin.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Estramustine can be decreased when it is combined with Aprotinin.Approved
Estrogens, esterifiedThe serum concentration of Estrogens, esterified can be decreased when it is combined with Aprotinin.Approved
Estrone sulfateThe serum concentration of Estrone sulfate can be decreased when it is combined with Aprotinin.Approved
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Aprotinin.Approved
Ethyl biscoumacetateThe therapeutic efficacy of Ethyl biscoumacetate can be decreased when used in combination with Aprotinin.Withdrawn
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Aprotinin.Approved
Fibrinogen Concentrate (Human)The risk or severity of adverse effects can be increased when Aprotinin is combined with Fibrinogen Concentrate (Human).Approved
FibrinolysinThe therapeutic efficacy of Fibrinolysin can be decreased when used in combination with Aprotinin.Approved
FluindioneThe therapeutic efficacy of Fluindione can be decreased when used in combination with Aprotinin.Investigational
FondaparinuxThe therapeutic efficacy of Fondaparinux can be decreased when used in combination with Aprotinin.Investigational
FosinoprilAprotinin may decrease the antihypertensive activities of Fosinopril.Approved
GarlicThe serum concentration of Aprotinin can be decreased when it is combined with Garlic.Approved
HeparinThe therapeutic efficacy of Heparin can be decreased when used in combination with Aprotinin.Approved, Investigational
HexestrolThe serum concentration of Hexestrol can be decreased when it is combined with Aprotinin.Withdrawn
HigenamineThe therapeutic efficacy of Higenamine can be decreased when used in combination with Aprotinin.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Aprotinin.Approved, Investigational
ImidaprilAprotinin may decrease the antihypertensive activities of Imidapril.Investigational
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Aprotinin.Approved
IndobufenThe therapeutic efficacy of Indobufen can be decreased when used in combination with Aprotinin.Investigational
Kct 0809The therapeutic efficacy of Kct 0809 can be decreased when used in combination with Aprotinin.Investigational
LepirudinThe therapeutic efficacy of Lepirudin can be decreased when used in combination with Aprotinin.Approved
LisinoprilAprotinin may decrease the antihypertensive activities of Lisinopril.Approved, Investigational
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Aprotinin.Approved, Investigational
MestranolThe serum concentration of Mestranol can be decreased when it is combined with Aprotinin.Approved
MethallenestrilThe serum concentration of Methallenestril can be decreased when it is combined with Aprotinin.Experimental
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Aprotinin.Approved, Illicit
MirtazapineThe serum concentration of Mirtazapine can be increased when it is combined with Aprotinin.Approved
MoexiprilAprotinin may decrease the antihypertensive activities of Moexipril.Approved
NadroparinThe therapeutic efficacy of Nadroparin can be decreased when used in combination with Aprotinin.Approved
NCX 4016The therapeutic efficacy of NCX 4016 can be decreased when used in combination with Aprotinin.Investigational
NefazodoneThe serum concentration of Nefazodone can be increased when it is combined with Aprotinin.Approved, Withdrawn
NitroaspirinThe therapeutic efficacy of Nitroaspirin can be decreased when used in combination with Aprotinin.Investigational
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with Aprotinin.Approved
OmapatrilatAprotinin may decrease the antihypertensive activities of Omapatrilat.Investigational
OpipramolThe serum concentration of Opipramol can be increased when it is combined with Aprotinin.Investigational
ParnaparinThe therapeutic efficacy of Parnaparin can be decreased when used in combination with Aprotinin.Approved
PerindoprilAprotinin may decrease the antihypertensive activities of Perindopril.Approved
PethidineThe risk or severity of adverse effects can be increased when Aprotinin is combined with Pethidine.Approved
PhenindioneThe therapeutic efficacy of Phenindione can be decreased when used in combination with Aprotinin.Approved
PhenprocoumonThe therapeutic efficacy of Phenprocoumon can be decreased when used in combination with Aprotinin.Approved
PimozideThe serum concentration of Pimozide can be increased when it is combined with Aprotinin.Approved
PlasminThe therapeutic efficacy of Plasmin can be decreased when used in combination with Aprotinin.Investigational
PrasugrelThe therapeutic efficacy of Prasugrel can be decreased when used in combination with Aprotinin.Approved
Protein CThe therapeutic efficacy of Protein C can be decreased when used in combination with Aprotinin.Approved
ProtriptylineThe serum concentration of Protriptyline can be increased when it is combined with Aprotinin.Approved
QuinaprilAprotinin may decrease the antihypertensive activities of Quinapril.Approved, Investigational
RamiprilAprotinin may decrease the antihypertensive activities of Ramipril.Approved
RescinnamineAprotinin may decrease the antihypertensive activities of Rescinnamine.Approved
ReteplaseThe therapeutic efficacy of Reteplase can be decreased when used in combination with Aprotinin.Approved
ReviparinThe therapeutic efficacy of Reviparin can be decreased when used in combination with Aprotinin.Approved
RiociguatThe serum concentration of Riociguat can be increased when it is combined with Aprotinin.Approved
RivaroxabanThe therapeutic efficacy of Rivaroxaban can be decreased when used in combination with Aprotinin.Approved
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Aprotinin.Approved, Investigational
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Aprotinin.Approved
SelexipagThe therapeutic efficacy of Selexipag can be decreased when used in combination with Aprotinin.Approved
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Aprotinin.Approved, Investigational
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Aprotinin.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Aprotinin.Approved
SpiraprilAprotinin may decrease the antihypertensive activities of Spirapril.Approved
St. John's WortThe metabolism of Aprotinin can be increased when combined with St. John's Wort.Nutraceutical
StreptokinaseThe therapeutic efficacy of Streptokinase can be decreased when used in combination with Aprotinin.Approved
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Aprotinin.Approved, Investigational
Synthetic Conjugated Estrogens, AThe serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Aprotinin.Approved
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Aprotinin.Approved, Investigational
TemocaprilAprotinin may decrease the antihypertensive activities of Temocapril.Experimental, Investigational
TemsirolimusThe risk or severity of adverse effects can be increased when Aprotinin is combined with Temsirolimus.Approved
TenecteplaseThe therapeutic efficacy of Tenecteplase can be decreased when used in combination with Aprotinin.Approved
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Aprotinin.Approved
TianeptineThe serum concentration of Tianeptine can be increased when it is combined with Aprotinin.Approved
TicagrelorThe therapeutic efficacy of Ticagrelor can be decreased when used in combination with Aprotinin.Approved
TiclopidineThe therapeutic efficacy of Ticlopidine can be decreased when used in combination with Aprotinin.Approved
TinzaparinThe therapeutic efficacy of Tinzaparin can be decreased when used in combination with Aprotinin.Approved
TipranavirThe serum concentration of Aprotinin can be decreased when it is combined with Tipranavir.Approved, Investigational
TirofibanThe therapeutic efficacy of Tirofiban can be decreased when used in combination with Aprotinin.Approved
TrandolaprilAprotinin may decrease the antihypertensive activities of Trandolapril.Approved
TreprostinilThe therapeutic efficacy of Treprostinil can be decreased when used in combination with Aprotinin.Approved, Investigational
TretinoinTretinoin may increase the thrombogenic activities of Aprotinin.Approved, Investigational, Nutraceutical
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Aprotinin.Approved
TriflusalThe therapeutic efficacy of Triflusal can be decreased when used in combination with Aprotinin.Approved
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Aprotinin.Approved
UrokinaseThe therapeutic efficacy of Urokinase can be decreased when used in combination with Aprotinin.Approved, Investigational, Withdrawn
Valproic AcidThe serum concentration of Valproic Acid can be decreased when it is combined with Aprotinin.Approved, Investigational
VerapamilThe metabolism of Verapamil can be decreased when combined with Aprotinin.Approved
VorapaxarThe therapeutic efficacy of Vorapaxar can be decreased when used in combination with Aprotinin.Approved
WarfarinThe therapeutic efficacy of Warfarin can be decreased when used in combination with Aprotinin.Approved
XimelagatranThe therapeutic efficacy of Ximelagatran can be decreased when used in combination with Aprotinin.Approved, Investigational, Withdrawn
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Aprotinin.Approved
Food InteractionsNot Available
References
Synthesis Reference

Marion Steinbuch, Jacques Chabbat, Olivier Taby, “Process for preparation of activated protein C by immobilized aprotinin chromatography.” U.S. Patent US5198534, issued February, 1985.

US5198534
General References
  1. Mahdy AM, Webster NR: Perioperative systemic haemostatic agents. Br J Anaesth. 2004 Dec;93(6):842-58. Epub 2004 Jul 26. [PubMed:15277296 ]
External Links
ATC CodesB02AB01
AHFS Codes
  • 20:28.16
PDB Entries
FDA labelDownload (108 KB)
MSDSDownload (19.5 KB)
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
SolutionIntravenous10000 unit
LiquidIntravenous100000 unit
PricesNot Available
PatentsNot Available
Properties
StateLiquid
Experimental Properties
PropertyValueSource
melting point>100 °CNot Available
Taxonomy
DescriptionNot Available
KingdomOrganic Compounds
Super ClassOrganic Acids
ClassCarboxylic Acids and Derivatives
Sub ClassAmino Acids, Peptides, and Analogues
Direct ParentPeptides
Alternative ParentsNot Available
SubstituentsNot Available
Molecular FrameworkNot Available
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Serine-type endopeptidase activity
Specific Function:
Has activity against the synthetic substrates Boc-Phe-Ser-Arg-Mec, Boc-Leu-Thr-Arg-Mec, Boc-Gln-Ala-Arg-Mec and Boc-Val-Pro-Arg-Mec. The single-chain form is more active than the two-chain form against all of these substrates.
Gene Name:
PRSS1
Uniprot ID:
P07477
Molecular Weight:
26557.88 Da
References
  1. Mahdy AM, Webster NR: Perioperative systemic haemostatic agents. Br J Anaesth. 2004 Dec;93(6):842-58. Epub 2004 Jul 26. [PubMed:15277296 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Serine-type endopeptidase activity
Specific Function:
Not Available
Gene Name:
CTRB1
Uniprot ID:
P17538
Molecular Weight:
27869.74 Da
References
  1. Mahdy AM, Webster NR: Perioperative systemic haemostatic agents. Br J Anaesth. 2004 Dec;93(6):842-58. Epub 2004 Jul 26. [PubMed:15277296 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Serine-type peptidase activity
Specific Function:
Plasmin dissolves the fibrin of blood clots and acts as a proteolytic factor in a variety of other processes including embryonic development, tissue remodeling, tumor invasion, and inflammation. In ovulation, weakens the walls of the Graafian follicle. It activates the urokinase-type plasminogen activator, collagenases and several complement zymogens, such as C1 and C5. Cleavage of fibronectin ...
Gene Name:
PLG
Uniprot ID:
P00747
Molecular Weight:
90568.415 Da
References
  1. Mahdy AM, Webster NR: Perioperative systemic haemostatic agents. Br J Anaesth. 2004 Dec;93(6):842-58. Epub 2004 Jul 26. [PubMed:15277296 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Serine-type endopeptidase activity
Specific Function:
Glandular kallikreins cleave Met-Lys and Arg-Ser bonds in kininogen to release Lys-bradykinin.
Gene Name:
KLK1
Uniprot ID:
P06870
Molecular Weight:
28889.425 Da
References
  1. Mahdy AM, Webster NR: Perioperative systemic haemostatic agents. Br J Anaesth. 2004 Dec;93(6):842-58. Epub 2004 Jul 26. [PubMed:15277296 ]
Comments
comments powered by Disqus
Drug created on February 12, 2009 09:44 / Updated on August 17, 2016 12:24